Mark Erickstad, MD
Urology · Longview, TXNPI 1972570307
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (47.0%), travel and lodging and education — rather than concentrated in one kind of arrangement. Teleflex LLC accounts for 61.4% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2022 at $1,757 and has fallen 83.9% since, to $283 in 2025. That places this record below the midpoint for urology clinicians in TX, where the typical reported total is $3,394.
Across 72 payments — averaging $46.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teleflex LLC$2K
- Astellas Pharma US Inc$223
- Axonics, Inc.$166
- Bayer$107
- Sumitomo Pharma America, Inc.$80
- AbbVie$75
- plus $634 from 19 others
What the payments were for
- Travel & lodging$1,52346%
- Food & beverage$1,56447%
- Education$2417%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teleflex LLC | 19 | $2,042 |
| Astellas Pharma US Inc | 4 | $223 |
| Axonics, Inc. | 8 | $166 |
| Bayer | 1 | $107 |
| Sumitomo Pharma America, Inc. | 3 | $80 |
| AbbVie(2 entities) | 5 | $75 |
| Tolmar Pharmaceuticals, Inc. | 2 | $69 |
| Boston Scientific | 3 | $58 |
| Inspire Medical Systems, Inc. | 3 | $57 |
| Tolmar, Inc. | 3 | $52 |
| Myovant Sciences Inc. | 3 | $48 |
| Rochester Medical Corporation | 2 | $44 |
| Hollister Incorporated | 3 | $42 |
| Olympus America Inc. | 2 | $42 |
| Novartis | 1 | $32 |
| Bioprotect Medical, Inc. | 1 | $27 |
| Cook Medical LLC | 1 | $26 |
| Urogen Pharma, Inc. | 1 | $23 |
| Blue Earth Diagnostics | 1 | $18 |
| Accord Healthcare, Inc. | 1 | $18 |
| Merck | 1 | $18 |
| Pfizer | 1 | $16 |
| Laborie Medical Technologies Corp. | 1 | $15 |
| Medtronic | 1 | $15 |
| Neotract Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$1,406
- UroLift System$384
- Xofigo$107
How this compares
$3,328 in reported general payments places this provider in the 45th percentile of 878 urology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 70 | $45,960 |
| ElmironPentosan Polysulfate Sodium | 15 | $18,147 |
| GemtesaVibegron | 22 | $16,310 |
| Tamsulosin Hcl | 889 | $13,201 |
| Doxycycline Monohydrate | 286 | $10,813 |
| Mirabegron ErMirabegron | 15 | $8,052 |
| Potassium Citrate ErPotassium Citrate | 68 | $7,147 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 197 | $5,810 |
| Finasteride | 456 | $4,758 |
| Solifenacin Succinate | 176 | $4,684 |
| Oxybutynin Chloride ErOxybutynin Chloride | 249 | $3,867 |
| Tolterodine Tartrate ErTolterodine Tartrate | 52 | $3,157 |
| Testosterone Cypionate | 54 | $2,602 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 146 | $2,095 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 26 | $1,485 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $223 | $45,96070 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $80 | $16,31022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 878 urology providers in Texas.
Other urology in Longview
- Andrew von EschenbachMontgomery$3.2M
- Brian MazzarellaLakeway$1.2M
- Arun RaiHouston$920K
- Allen MoreyDallas$914K
- Donald GriffithHouston$732K
- Michael TrotterAustin$590K
- Vitaly MargulisDallas$555K
- Daniel SaltzsteinSan Antonio$547K
- Leroy JonesSan Antonio$506K
- Jonathan Clavell HernandezHouston$500K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.